Evidence map›Paper›PMID 39096931›Full record

ArticleThe lancet. Psychiatry2024

Cognitive and psychiatric symptom trajectories 2-3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.

Maxime Taquet, Zuzanna Skorniewska, Thomas De Deyn, Adam Hampshire, William R Trender, Peter J Hellyer, James D Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks and 25 more

Abstract read
In one paragraph

Article in The lancet. Psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Cognitive Trajectories After Hospitalization for COVID-19: A 36-Month Longitudinal Study.The Journal of neuropsychiatry and clinical neurosciences · 2026
    Article
  12. Article
  13. Cognitive consequences of COVID-19 infection: current evidence and future directions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Maxime TaquetDepartment of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford, UK. Electronic address: maxime.taquet@msd.ox.ac.uk.
Zuzanna SkorniewskaDepartment of Psychiatry, University of Oxford, Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
Thomas De DeynDepartment of Psychiatry, University of Oxford, Oxford, UK.
Adam HampshireDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
William R TrenderDepartment of Brain Sciences, Imperial College London, London, UK.
Peter J HellyerDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
James D ChalmersUniversity of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Ling-Pei HoMRC Translational Immune Discovery Unit, University of Oxford, Oxford, UK.
Alex HorsleyDivision of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester University NHS Foundation Trust, Manchester, UK.
Michael MarksDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, University College London Hospital, London, UK; Division of Infection and Immunity, University College London, London, UK.
Krisnah PoinasamyAsthma and Lung UK, London, UK.
Betty RamanRadcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Olivia C LeavyDepartment of Population Health Sciences, University of Leicester, Leicester, UK.
Matthew RichardsonThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Omer ElneimaThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Hamish J C McAuleyThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Aarti ShikotraNIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Amisha SingapuriThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Marco SerenoThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Ruth M SaundersThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Victoria C HarrisThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Natalie RogersLong Covid Support, England and Wales, UK.
Linzy Houchen-WolloffThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK; Therapy Department, University Hospitals of Leicester NHS Trust, Leicester, UK.
Neil J GreeningThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
Parisa MansooriMQ: Transforming Mental Health, London, UK.
Ewen M HarrisonCentre for Medical Informatics, University of Edinburgh, Edinburgh, UK.
Annemarie B DochertyCentre for Medical Informatics, University of Edinburgh, Edinburgh, UK.
Nazir I LonePopulation Health Sciences, The Usher Institute, University of Edinburgh, Edinburgh, UK; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.
Jennifer QuintNational Heart and Lung Institute, Imperial College London, London, UK.
Christopher E BrightlingThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Louise V WainDepartment of Population Health Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
Rachael A EvansThe Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
John R GeddesDepartment of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
Paul J HarrisonDepartment of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford, UK.
PHOSP-COVID Study Collaborative Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is known to be associated with increased risks of cognitive and psychiatric outcomes after the acute phase of disease. We aimed to assess whether these symptoms can emerge or persist more than 1 year after hospitalisation for COVID-19, to identify which early aspects of COVID-19 illness predict longer-term symptoms, and to establish how these symptoms relate to occupational functioning.

methodsThe Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study of adults (aged ≥18 years) who were hospitalised with a clinical diagnosis of COVID-19 at participating National Health Service hospitals across the UK. In the C-Fog study, a subset of PHOSP-COVID participants who consented to be recontacted for other research were invited to complete a computerised cognitive assessment and clinical scales between 2 years and 3 years after hospital admission. Participants completed eight cognitive tasks, covering eight cognitive domains, from the Cognitron battery, in addition to the 9-item Patient Health Questionnaire for depression, the Generalised Anxiety Disorder 7-item scale, the Functional Assessment of Chronic Illness Therapy Fatigue Scale, and the 20-item Cognitive Change Index (CCI-20) questionnaire to assess subjective cognitive decline. We evaluated how the absolute risks of symptoms evolved between follow-ups at 6 months, 12 months, and 2-3 years, and whether symptoms at 2-3 years were predicted by earlier aspects of COVID-19 illness. Participants completed an occupation change questionnaire to establish whether their occupation or working status had changed and, if so, why. We assessed which symptoms at 2-3 years were associated with occupation change. People with lived experience were involved in the study.

findings2469 PHOSP-COVID participants were invited to participate in the C-Fog study, and 475 participants (191 [40·2%] females and 284 [59·8%] males; mean age 58·26 [SD 11·13] years) who were discharged from one of 83 hospitals provided data at the 2-3-year follow-up. Participants had worse cognitive scores than would be expected on the basis of their sociodemographic characteristics across all cognitive domains tested (average score 0·71 SD below the mean [IQR 0·16-1·04]; p<0·0001). Most participants reported at least mild depression (263 [74·5%] of 353), anxiety (189 [53·5%] of 353), fatigue (220 [62·3%] of 353), or subjective cognitive decline (184 [52·1%] of 353), and more than a fifth reported severe depression (79 [22·4%] of 353), fatigue (87 [24·6%] of 353), or subjective cognitive decline (88 [24·9%] of 353). Depression, anxiety, and fatigue were worse at 2-3 years than at 6 months or 12 months, with evidence of both worsening of existing symptoms and emergence of new symptoms. Symptoms at 2-3 years were not predicted by the severity of acute COVID-19 illness, but were strongly predicted by the degree of recovery at 6 months (explaining 35·0-48·8% of the variance in anxiety, depression, fatigue, and subjective cognitive decline); by a biocognitive profile linking acutely raised D-dimer relative to C-reactive protein with subjective cognitive deficits at 6 months (explaining 7·0-17·2% of the variance in anxiety, depression, fatigue, and subjective cognitive decline); and by anxiety, depression, fatigue, and subjective cognitive deficit at 6 months. Objective cognitive deficits at 2-3 years were not predicted by any of the factors tested, except for cognitive deficits at 6 months, explaining 10·6% of their variance. 95 of 353 participants (26·9% [95% CI 22·6-31·8]) reported occupational change, with poor health being the most common reason for this change. Occupation change was strongly and specifically associated with objective cognitive deficits (odds ratio [OR] 1·51 [95% CI 1·04-2·22] for every SD decrease in overall cognitive score) and subjective cognitive decline (OR 1·54 [1·21-1·98] for every point increase in CCI-20).

interpretationPsychiatric and cognitive symptoms appear to increase over the first 2-3 years post-hospitalisation due to both worsening of symptoms already present at 6 months and emergence of new symptoms. New symptoms occur mostly in people with other symptoms already present at 6 months. Early identification and management of symptoms might therefore be an effective strategy to prevent later onset of a complex syndrome. Occupation change is common and associated mainly with objective and subjective cognitive deficits. Interventions to promote cognitive recovery or to prevent cognitive decline are therefore needed to limit the functional and economic impacts of COVID-19.

fundingNational Institute for Health and Care Research Oxford Health Biomedical Research Centre, Wolfson Foundation, MQ Mental Health Research, MRC-UK Research and Innovation, and National Institute for Health and Care Research.

Indexed as

COVID-19HospitalizationAdultAgedAnxietyCognitionCognitive DysfunctionDepressionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsProspective StudiesSARS-CoV-2

Identifiers

PMID39096931
PMCPMC7618856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.